Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News bluebird bio Inc. BLUEV


Primary Symbol: BLUE

bluebird bio Inc is a clinical-stage biotechnology company that develops gene therapies for severe genetic and rare diseases. The company's gene therapy procedures aim to genetically modify a patient's cells to fundamentally correct or address the genetic basis underlying a disease. Bluebird's revenue is derived from collaboration arrangements, research fees, license fees, and grant revenue. The company works with industry peers, strategic partners, and nonprofit organizations for the development and commercialization of its product candidates.


Recent & Breaking News (NDAQ:BLUE)

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of bluebird bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 13, 2021 - BLUE

Newsfile March 1, 2021

BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.

GlobeNewswire March 1, 2021

INVESTOR DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA March 1, 2021

Breaking Notice: Rosen, a Globally Recognized Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - BLUE

Business Wire February 27, 2021

bluebird bio to Present at Cowen Health Care Conference

Business Wire February 26, 2021

BLUE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - BLUE

ACCESSWIRE IA February 25, 2021

BLUE ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of April 13, 2021 in the Class Action Filed on Behalf of bluebird bio, Inc. Limited Shareholders

Newsfile February 25, 2021

DEADLINE ALERT for BLUE, EH, JT, and IMVT: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

GlobeNewswire February 25, 2021

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of bluebird bio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of April 13, 2021 - BLUE

Newsfile February 24, 2021

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against iRhythm Technologies, Tyson Foods, Clover Health Investments, and bluebird bio and Encourages Investors to Contact the Firm

GlobeNewswire February 24, 2021

The New England Journal of Medicine Publishes Results from Pivotal Phase 2 KarMMa Study of Idecabtagene Vicleucel (Ide-cel, bb2121), an Investigational BCMA-Directed CAR T Cell Therapy

Business Wire February 24, 2021

BLUE SHAREHOLDER FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Has Been Filed Against bluebird bio, Inc.

GlobeNewswire February 24, 2021

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

Business Wire February 24, 2021

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

ACCESSWIRE IA February 24, 2021

BLUE Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Reminds bluebird bio, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm

Business Wire February 24, 2021

BLUE ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against bluebird bio, Inc.- BLUE

GlobeNewswire February 24, 2021

Breaking Alert: Rosen, A Trusted and Leading Law Firm, Encourages bluebird bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - BLUE

Newsfile February 23, 2021

bluebird bio Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Operational Progress

Business Wire February 23, 2021

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

Newsfile February 23, 2021

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)

Business Wire February 23, 2021